| |
Introduction Ricardo V. Lloyd, M.D., Ph.D., Department of Pathology, Mayo Clinic, Rochester, MN |
| |
Papillary Thyroid Carcinoma Virginia LiVolsi, M.D., Hospital of the University of Pennsylvania, Philadelphia, PA |
 | To understand the cytologic and histologic nuclear features of papillary thyroid carcinoma and the minimum criteria for diagnosis. |
 | To recognize the disorders in which the nuclei mimic those of papillary carcinoma, including thyroiditis, autoimmune hyperthyroidism and other rare lesions. |
 | To identify the important variants of papillary thyroid carcinoma, criteria for their diagnosis and their clinical implications. |
| |
Follicular Thyroid Carcinoma Manuel Sobrinho-Simoes, M.D., Ph.D., Medical Faculty Hospital de S. Joao, Porto, Portugal |
 | To review the histologic criteria for diagnosing minimally invasive, angioinvasive and widely invasive follicular carcinoma. |
 | To discuss the differential diagnosis of minimally invasive carcinoma vs encapsulated follicular variant of papillary carcinoma and of widely invasive follicular carcinoma vs poorly differentiated carcinoma. |
 | To illustrate, where appropriate, the diagnostic and/or prognostic/therapeutic role of special studies including immunohistochemistry and molecular pathology. |
| |
Familial Thyroid Cancer Vania Nosé, M.D., Ph.D., Brigham and Women’s Hospital, Boston, MA |
 | To discuss differences between sporadic and familial thyroid carcinomas. |
 | To discuss familial medullary thyroid carcinoma as a component of familial syndromes including multiple endocrine neoplasia 2A, multiple endocrine neoplasia 2B, familial adenomatous polyposis and phosphatase and tensin homolog deleted on chromosome 10 (PTEN)-hamartoma tumor syndromes. |
 | Emphasize the critical role of the pathologist in the identification of these syndromes by recognizing characteristic patterns of thyroid pathology. |
| |
Molecular Analysis of Thyroid Tumors Yuri Nikiforov, M.D., Ph.D., University of Pittsburgh, Pittsburgh, PA |
 | To provide an overview of molecular alterations in thyroid tumors. |
 | To discuss specimen requirements for molecular testing in thyroid samples. |
 | To discuss the diagnostic and prognostic utility of specific molecular markers in thyroid surgical resections and fine needle aspiration (FNA) samples. |
| |
Targeted Therapy for Thyroid Tumors Steven Sherman, M.D., University of Texas, MD Anderson Cancer Center, Houston, TX |
 | To provide an overview of currently available and emerging targeted therapies for thyroid tumors. |
 | To review the biological and clinical background for BRAF- and RET-targeted drugs. |
 | To discuss the role of pathologic evaluation and molecular testing in selecting patients for targeted therapy and monitoring side effects. |
| |
Introduction to Other Endocrine Tumors Yuri Nikiforov, M.D., Ph.D., University of Pittsburgh, Pittsburgh, PA |
| |
The neural crest saga and its impact on our perception of neuroendocrine tumors (with a coda) Juan Rosai, M.D., Centro Consulenze Anatomia Patologica Oncologica, Milan, Italy |
 | To describe the role of the neural crest in the development of the vertebrate embryo. |
 | To analyze the techniques used to document the neural crest origin of various cell types and the tumors arising from them, with emphasis on LeDouarin’s quail-chick chimera model. |
 | To summarize the current beliefs concerning neural crest derivatives in the human body, with emphasis on new molecular markers. |
 | To briefly raise a phylogenetic consideration as a possible variation on the theme. |
| |
Adrenal Cortical and Medullary Tumors Ricardo V. Lloyd, M.D., Ph.D., Mayo Clinic, Rochester, MN |
 | To review the practical diagnostic approaches to the classification of adrenal cortical and medullary tumors. |
 | To discuss the use of ancillary technologies in the differential diagnosis of adrenal cortical and medullary tumors. |
 | To discuss molecular findings associated with the development of pheochromocytomas and paragangliomas. |
| |
Pancreatic Endocrine Tumors Sylvia Asa, M.D., Ph.D., Princess Margaret Hospital, Toronto, Canada |
 | To review the critical morphologic and immunohistochemical features involved in the diagnosis of pancreatic endocrine tumors. |
 | To understand the molecular basis of familial and sporadic pancreatic endocrine tumors. |
 | To identify predictive and prognostic markers and therapeutic options for pancreatic endocrine malignancies. |
| |
Parathyroid Tumors Ronald DeLellis, M.D., Lifespan Academic Medical Center, RI Hospital, Providence, RI |
 | To review the practical diagnostic approaches to the classification of hyperplastic and neoplastic disorders of the parathyroid glands. |
 | To review the roles of ancillary technologies (immunohistochemistry and molecular genetic analyses) in the differential diagnosis of hyperparathyroidism. |
 | To review contemporary radiological approaches, and the use of intraoperative parathyroid hormone assays in the planning of surgical therapy for patients with hyperparathyroidism. |